Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis. - PubMed - NCBI

Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis. - PubMed - NCBI

Oncotarget. 2017 Mar 7. doi: 10.18632/oncotarget.15972. [Epub ahead of print]

Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.

Shen H1, Che K2, Cong L1, Dong W3, Zhang T1, Liu Q2, Du J2,3.

Author information

Abstract

Circulating tumor DNA (ctDNA) and tumor cells (CTC) are novel approaches for identifying genomic alterations. Thus, we designed a meta-analysis to evaluate the diagnostic value and prognostic significance of a KRAS proto-oncogene, GTPase (KRAS) mutation for lung cancer patients. All included articles were from PubMed, EMBASE, Web of Science and Cochrane Library. Twelve articles that described 1,131 patients were reviewed. True positives (TP), false positives (FP), true negatives (TN), and false negatives (FN) were used to calculate pooled sensitivity, specificity, the positive likelihood ratio (PLR), the negative likelihood ratio (NLR), a diagnostic odds ratio (DOR), the area under the curve (AUC) and corresponding 95% confidence intervals (95% CI). PLR is calculated as sensitivity/(1-specificity) and NLR is (1- sensitivity)/specificity. DOR is a measured of diagnostic effectiveness (PLR/NLR). A survival analysis subgroup was also designed to evaluate prognostic significance. Pooled sensitivity, specificity, PLR, NLR, DOR and AUC were 0.79 (95% CI, 0.63-0.89), 0.93 (95% CI, 0.89-0.96), 12.13 (92% CI, 7.11-20.67), 0.22 (95% CI, 0.12-0.41), 54.82 (95% CI, 23.11-130.09), and 0.95 (95% CI, 0.93-0.96), respectively. KRAS mutation and wild-type hazard ratios for overall survival and progression-free survival were 1.37 (95% CI, 1.08-1.66), 1.46 (95% CI, 1.15-1.77) in blood samples, and 1.16 (95% CI, 1.03-1.28), 1.28 (95% CI, 1.09-1.46) in tumor tissue.

KEYWORDS:

KRAS; blood; diagnostic test; lung cancer; predictive factor

PMID:

 

28415658

 

DOI:

 

10.18632/oncotarget.15972

Free full text

Last Posted: Apr 20, 2017

---

• Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.  
  Shen Hongchang et al. Oncotarget 2017 Mar
• Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.  
  Akerley Wallace L et al. Current medical research and opinion 2017 Mar 1-7
• Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.  
  DiStasio Marcello et al. Clinical lung cancer 2017 Mar
• Multimodal lung cancer screening using the ITALUNG Biomarker Panel and Low Dose Computed Tomography. Results of the ITALUNG biomarker study.  
  Carozzi Francesca Maria et al. International journal of cancer 2017 Apr
• Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.  
  Cheema P K et al. Current oncology (Toronto, Ont.) 2017 Feb 24(1) 16-22
• Screening and Early Detection of Lung Cancer.  
  Eggert Julie et al. Seminars in oncology nursing 2017 Apr
• Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.  
  Shu Yongqian et al. Scientific reports 2017 Apr 7(1) 583
• Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.  
  Yamamoto Gou et al. International journal of oncology 2017 Mar
• Synthesis and the interaction of 2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-f][1,10]phenanthrolines with telomeric DNA as lung cancer inhibitors.  
  Liu Jiachun et al. European journal of medicinal chemistry 2017 Mar 13336-49
• Noninvasive strategies for lung cancer testing  
  NIH Research Matters, March 7, 2017
• Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.  
  Armstrong Katrina et al. Cancer 2016 122(9) 1338-42
• Noninvasive strategies for lung cancer testing  
  NIH Research Matters, March 7, 2017
• Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.  
  Zheng Gang et al. American journal of clinical pathology 2016 May 145(5) 696-702
• Personalized Medicine in Respiratory Disease: Role of Proteomics.  
  Priyadharshini V S et al. Advances in protein chemistry and structural biology 2016 102115-46
• Targeted pharmacotherapy after somatic cancer mutation screening.  
  Polasek Thomas M et al. F1000Research 2016 51551
• The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.  
  Biernacka Anna et al. Cancer genetics 2016 May 209(5) 195-8

more